Anti-TNFα therapy in IBD patients was associated with increased odds of exacerbation and decompensation (Hazard ratio: 1.23, 95% confidence interval: 1.11-1.46; P < 0.05; I2 =23%). Here, TNF is linked to inflammatory bowel disease.